The reduction of cell death and proliferation by p27 Kip1 minimizes DNA damage in an experimental model of genotoxicity

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2270-2280

  Ranchal, Isidora ^a,c   González, Raúl ^a,c   Bello, Rosario I ^a   Ferrín, Gustavo ^a,c   Hidalgo, Ana B ^a   Linares, Clara I ^a   Aguilar Melero, Patricia ^a   González Rubio, Sandra ^a   Barrera, Pilar ^a,c   Marchal, Trinidad ^a,c   Nakayama, Keiichi I ^b   De La Mata, Manuel ^a,c   Muntané, Jordi ^a,c  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b KYUSHU UNIVERSITY   (Japan)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AFB 1; Cell cycle; HCC; p21; p27

Indexed keywords

AFLATOXIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

AFLATOXIN B1; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DNA DAMAGE; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349861914     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24621     Document Type: Article

References (52)

1. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 2001;39:109-118
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-S37.
4. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998;4:1475-1482 (Pubitemid 28265231)
5. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-322
6. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-1021 (Pubitemid 30169952)
7. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207 (Pubitemid 36169630)
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 (Pubitemid 36152543)
9. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993;53:2884-2887 (Pubitemid 23180531)
10. Piao Z, Kim H, Jeon BK, Lee WJ, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997;80:865-872 (Pubitemid 27360467)
11. Gorrin Rivas MJ, Arii S, Furutani M, Harada T, Mizumoto M, Nishiyama H, Fujita J, Imamura M. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 1998;28:986-993 (Pubitemid 28450259)
12. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90-99 (Pubitemid 29300574)
13. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mössner J, Engeland K, Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999;91:1154-1158 (Pubitemid 29330554)
14. Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T, Suzuki Y, Naito A, Igarashi H, Yanagi M, Takahashi T, Asakura H. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998;27:402-406 (Pubitemid 28081053)
15. Jackson PE, Groopman JD. Aflatoxin and liver cancer. Baillieres Best Pract Res Clin Gastroenterol 1999;13:545-555
16. Garner RC, Miller EC, Miller JA. Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972;32:2058-2066
17. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428 (Pubitemid 21912245)
18. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431 (Pubitemid 21912246)
19. Tashiro F, Morimura S, Hayashi K, Makino R, Kawamura H, Horikoshi N, Nemoto K, Ohtsubo K, Sugimura T, Ueno Y. Expression of the c-Ha-ras and c-myc genes in aflatoxin B1-induced hepatocellular carcinomas. Biochem Biophys Res Commun 1986;138:858-864 (Pubitemid 16013211)
20. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219
21. Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002;59:126-142 (Pubitemid 34117361)
22. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512
23. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 1996;7:135-146 (Pubitemid 26049822)
24. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74. (Pubitemid 24228301)
25. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998;95:1091-1096 (Pubitemid 28124917)
26. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-17. (Pubitemid 30130220)
27. Qin LF, Ng IO. Expression of p27 (KIP1) and p21 (WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 2001;32:778-784
28. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Kockerling F, Haugwitz U, Wasner M, Hauss J, Engeland K, Wittekind C. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000;89:350-355 (Pubitemid 30620288)
29. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000;6:3966-3972 (Pubitemid 30807089)
30. Armengol C, Boix L, Bachs O, Sole M, Fuster J, Sala M, Llovet JM, Rodés J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 2003;38:591-597 (Pubitemid 36560643)
31. KIP1. Cell Mol Life Sci 2008;65:3255-3264
32. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
33. 60Co gamma-irradiation in hepatocellular carcinoma HepG2 cell line. World J Gastroenterol 2004;10:3103-3106
34. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del SG, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685
35. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
36. Taffs RE, Sitkovsky M. In vitro assays for mouse B and T lymphocyte function. New York: Greene Publishing, 1991.3.16.1-3.16.8.
37. Pedersen SB, Amtssygehus A. Multiplex relative gene expression analysis by real-time RT-PCR using the iCycler iQ detection system, 107th edn. New York: Cold Spring Harbor Press and Higwire Press, 2001.10-14.
38. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG. A growth factor-dependent nuclear kinase phosphorylates p27 (kip1) and regulates cell cycle progression. EMBO J 2002;21:3390-3401 (Pubitemid 34760571)
39. Fujita N, Sata S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-28713
40. Fujita N, Sata S, Katayama K, Tsuruo T. Phosphorylation of p27kip1 at threonine 198 by p90 ribosomal protein S6 kinase promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2003;278:49254-49260
41. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90-99 (Pubitemid 29300574)
42. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 1983;80:2695-2698
43. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C, Crary GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998;16:2141-2150 (Pubitemid 28211689)
44. Kato A, Ota S, Bamba H, Wong RM, Ohmura E, Imai Y, Matsuzaki F. Regulation of cyclin D-dependent kinase activity in rat liver regeneration. Biochem Biophys Res Commun 1998;245:70-74 (Pubitemid 28414248)
45. Ilyin GP, Glaise D, Gilot D, Baffet G, Guguen-Guillouzo C. Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth. Am J Physiol Gastrointest Liver Physiol 2003;285:G115-27. (Pubitemid 36736395)
46. Islaih M, Halstead BW, Kadura IA, Li B, Reid-Hubbard JL, Flick L, Altizer JL, Thom Deahl J, Monteith DK, Newton RK, Watson DE. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res 2005;578:100-116 (Pubitemid 41395315)
47. Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J Biol Chem 2004;279:13496-13505
48. Kwon YH, Jovanovic A, Serfas MS, Kiyokawa H, Tyner AL. p21 functions to maintain quiescence of p27-deficient hepatocytes. J Biol Chem 2002;277:41417-41422 (Pubitemid 35257442)
49. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649
50. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-649
51. Kwon YH, Jovanovic A, Serfas MS, Tyner AL. The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury. J Biol Chem 2003;278:30348-30355 (Pubitemid 36962429)
52. Payne SR, Zhang S, Tsuchiya K, Moser R, Gurley KE, Longton G, De Boer J, Kemp CJ. p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability. Mol Cell Biol 2008;28:258-268